Qingdao Baheal Medical INC. (301015) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.47x

Qingdao Baheal Medical INC. (301015) has a Cash Flow Reinvestment Rate of 0.47x as of September 2025, reinvesting CN¥107.50 Million (capex CN¥107.50 Million ) from operating cash flow of CN¥230.38 Million. Check how high is Qingdao Baheal Medical INC.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.47x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥107.50 Million
Capex + Investments

Operating Cash Flow

CN¥230.38 Million
CNY

Capital Expenditures

CN¥107.50 Million
CNY

Qingdao Baheal Medical INC. Cash Flow Reinvestment Rate (2018–2025)

Historical reinvestment intensity for Qingdao Baheal Medical INC. across 7 annual periods. Explore 301015 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Qingdao Baheal Medical INC. (2018–2025)

Year-by-year capital reinvestment analysis for Qingdao Baheal Medical INC.. For live market cap and broader valuation context, see 301015 stock market capitalisation.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2025 0.63x CN¥589.21 Million CN¥934.45 Million CN¥288.93 Million ▼ -30.1%
2024 0.90x CN¥734.15 Million CN¥813.85 Million CN¥303.99 Million ▲ +109.0%
2023 0.43x CN¥345.01 Million CN¥799.50 Million CN¥185.49 Million ▼ -40.7%
2022 0.73x CN¥222.65 Million CN¥305.75 Million CN¥105.32 Million ▲ +162.4%
2021 0.28x CN¥50.31 Million CN¥181.30 Million CN¥27.49 Million ▲ +92.5%
2019 0.14x CN¥6.63 Million CN¥45.96 Million CN¥2.95 Million ▼ -49.2%
2018 0.28x CN¥15.74 Million CN¥55.50 Million CN¥15.74 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow